Biotech Values

[stocksrising]

Bluepoint Med takeover by Sanofi

Joint Press Release issued on June 2, 2025 by Sanofi and Blueprint Medicines Corporation
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
PR Newswire

Under the terms of the acquisition, Sanofi (SNY.NaE) will pay $129.00 per share in cash at closing, representing an equity value of approximately $9.1 billion. Blueprint shareholders also will receive one non-tradeable contingent value right (CVR) which will entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis.